PPARD and primary biliary cholangitis: Seladelpar is a selective PPARδ agonist that has documented anticholestatic, anti-inflammatory, and antipruritic effects.19,20 This phase 3, randomized, placebo-controlled study evaluated the efficacy of adding seladelpar (5 or 10 mg) to UDCA or using seladelpar as monotherapy in patients with PBC at high risk for progression.